We evaluated virological response and resistance profile in virologically suppressed individuals switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in real-life.
Armenia, D., Forbici, F., Bertoli, A., Berno, G., Malagnino, V., Gagliardini, R., et al. (2022). Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE [10.1016/j.jgar.2022.06.027].
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
Armenia, D;Bertoli, A;Malagnino, V;Buonomini, A;Teti, E;Sarmati, L;Andreoni, M;Perno, C F;Ceccherini-Silberstein, F;Santoro, M
2022-07-03
Abstract
We evaluated virological response and resistance profile in virologically suppressed individuals switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in real-life.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2213716522001618-main.pdf
accesso aperto
Licenza:
Non specificato
Dimensione
1.19 MB
Formato
Adobe PDF
|
1.19 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
